NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. (“RAPT” or the “Company”) RAPT. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.

The investigation concerns whether RAPT and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On March 14, 2023, Rapt issued a press release in which the company announced, among other things, that “[f]For our phase 2b trial of RPT193 in atopic dermatitis, we now expect top-line results in mid-2024 as recent patient enrollment has been slower than expected as we did not see the seasonal increase that we had anticipated.”

Following news of the delay, Rapt’s stock price fell $5.00 per share, or 20.24%, to close at $19.70 per share on March 14, 2023.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, fiduciary breaches and corporate wrongdoing. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomlaw.com.

CONTACT:
Robert S Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980